Company Profile
Emergent BioSolutions Stock Price, News & Analysis
Company overview
Business overview
Emergent BioSolutions is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NYSE, Emergent BioSolutions is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Emergent BioSolutions follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Emergent BioSolutions sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
EBS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Emergent BioSolutions’ catalysts are biodefense contract awards, manufacturing execution, and any update on its public-health products. The market will care about whether the company can keep its federal-defense and infectious-disease franchise stable.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
Source: Emergent BioSolutions
- 02
- 03
- 04
- 05
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
Source: Emergent BioSolutions
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.